Drug Profile
SAR 441236
Alternative Names: SAR441236; Trispecific broadly neutralising antibodyLatest Information Update: 11 Mar 2024
Price :
$50
*
At a glance
- Originator National Institute of Allergy and Infectious Diseases; Sanofi; The Scripps Research Institute
- Developer National Institute of Allergy and Infectious Diseases; Sanofi
- Class Antiretrovirals; Antivirals; Monoclonal antibodies; Proteins; Trispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HIV infections
Most Recent Events
- 05 Mar 2024 Pharmacokinetics and adverse events data from a phase I trial in HIV-infections were released by ModeX Therapeutics
- 28 Jan 2024 No recent reports of development identified for phase-I development in HIV-infections in USA (IV, Infusion)
- 24 Jan 2024 Phase-I clinical trials in HIV infections in USA (Parenteral) before January 2024 (ModeX Therapeutics pipeline, January 2024)